Prosecution Insights
Last updated: November 08, 2026

BIRDIE BIOPHARMACEUTICALS, INC.

Technology area: Biotechnology & Pharmaceuticals

2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready

Analysis

BIRDIE BIOPHARMACEUTICALS, INC. operates in the Biotechnology & Pharmaceuticals technology area. The company has 1 pending office action. This action is handled by 1 distinct examiner and 1 distinct art unit. This suggests a focused intellectual property strategy within the pharmaceutical sector.

JOHNSON, CHRISTOPHER LINDSAY is the busiest examiner for this portfolio. This examiner is currently managing 1 pending office action. With 1 distinct examiner and 1 pending office action total, the workload is entirely concentrated. This suggests a focused interaction with the patent office for the company's current matters. For the practitioner, this means that JOHNSON, CHRISTOPHER LINDSAY is the sole arbiter of the company's current pending claims. The presence of 1 distinct art unit further emphasizes the specialized nature of the technology under review. This centralized prosecution profile, featuring 1 pending office action, indicates that the company's immediate patent office activity is limited to a specific technical area within the biotechnology domain.

Written from this page's own data; every figure is computed from USPTO records and verified before publication.

Portfolio Summary

2
Total Pending OAs
1
Non-Final OAs
1
Final Rejections
0
Advisory / Quayle

Case Difficulty Mix

Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.

2
Hard (100%)
0
Medium (0%)
0
Easy (0%)
0
Unknown (0%)

Rejection Statute Mix

BucketCases
Multi-statute (no §101)2 (100%)

Industry Mix

How the docket's pending cases split across USPTO tech-center bands.

2
Life Sciences
100% of docket
0
Information Tech
0% of docket
0
Communications
0% of docket
0
Semiconductors
0% of docket
0
Mechanical / Eng
0% of docket
0
Business / Other
0% of docket

Time-on-OA Estimate

Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.

20 h
Manual time on pending OAs
4 h
Time saved (low, 20%)
7 h
Time saved (mid, 35%)
0.2 wks
FTE-weeks freed (mid)

Top Examiners on this docket

ExaminerApps on this docketAllow rateInterview lift
GODDARD, LAURA B 1 51.0% +13.4%
JOHNSON, CHRISTOPHER LINDSAY 1 47.2% +79.2%

Hard Cases (2)

Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.

App #TitleExaminerDue in
19258590 ANTI-PD-L1 COMBINATIONS FOR TREATING TUMORS GODDARD, LAURA B —
18023306 CANCER TREATMENT WITH TLR AGONIST JOHNSON, CHRISTOPHER LINDSAY —

Interview Candidates (2)

Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.

App #TitleExaminerDue in
19258590 ANTI-PD-L1 COMBINATIONS FOR TREATING TUMORS GODDARD, LAURA B —
18023306 CANCER TREATMENT WITH TLR AGONIST JOHNSON, CHRISTOPHER LINDSAY —

Top Art Units

Art UnitApps
1642 1
1691 1

Pending Office Actions

App #TitleExaminerArt UnitStatutesStatusDue inAIFiled
19258590 ANTI-PD-L1 COMBINATIONS FOR TREATING TUMORS GODDARD, LAURA B 1642 §102§103Other Final Rejection — Pending Jul 02, 2025
18023306 CANCER TREATMENT WITH TLR AGONIST JOHNSON, CHRISTOPHER LINDSAY 1691 §103§112 Non-Final OA — Pending Aug 11, 2023

Managing BIRDIE BIOPHARMACEUTICALS, INC.'s Patent Portfolio?

IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Frequently Asked Questions

How many pending USPTO office actions does BIRDIE BIOPHARMACEUTICALS, INC. have?

BIRDIE BIOPHARMACEUTICALS, INC. has 2 pending office actions as of November 2026, spread across 2 art units and 2 examiners.

Which USPTO examiner handles the most BIRDIE BIOPHARMACEUTICALS, INC. applications?

Laura B Goddard has the most, with 1 of BIRDIE BIOPHARMACEUTICALS, INC.'s pending office actions.

What technology area are BIRDIE BIOPHARMACEUTICALS, INC.'s patent applications in?

Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month